Navigation Links
Emissary Capital Group Initiates Coverage on Sinobiopharma
Date:9/21/2009

NEW YORK, Sept. 21 /PRNewswire/ -- Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) with a Buy rating and target price of $1.00-$1.25. Jiangsu, China-based SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products. The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and cardiovascular-related products related to high blood pressure (commercial in October 2009). KuTai, SNBP's flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures. The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University.

About Emissary Capital Group

Emissary Capital Group, Inc. is a New York City-based company that provides strategic consulting and research services to emerging growth companies primarily based in India and China. The firm provides a diversified array of services to small and medium sized private companies, generally defined as those with annual revenues under $200 million, in order to assist them to become publicly traded companies in the U.S. For more information, please visit www.emissarycapital.com

    Contact:
    Albert Lee
    Emissary Capital Group, LLC
    1-212-297-6218


'/>"/>
SOURCE Emissary Capital Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
4. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
5. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
7. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
8. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
9. Altheus Therapeutics Secures $3.6 Million in Venture Capital
10. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):